Ocean Biomedical (NASDAQ: OCEA) Announces 70% Increase in Price Target by EF Hutton from $10 to $17 on New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody
The groundbreaking research uncovers in detail how the suppression of Chi3L1 works to keep glioma stem cells from differentiating into the most aggressive forms of glioblastoma.
- The groundbreaking research uncovers in detail how the suppression of Chi3L1 works to keep glioma stem cells from differentiating into the most aggressive forms of glioblastoma.
- This data provides further evidence of the therapeutic potential of Ocean’s anti-Chi3L1 for solid tumors.
- Dr. Elias' previous work has demonstrated the multifaceted role that Chi3L1 plays in other solid tumor types such as melanoma and lung cancer.”
“Dr. - All reports on OCEA prepared by analysts represent the views of such analysts and are not necessarily those of OCEA.